- TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome - - On track to achieve 2026 financial guidance - CARLSBAD, Calif.
Ionis reports second quarter 2026 financial results and highlights progress on key programs
calendar_today
July 29, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals